Federal Kratom Consumer Protection Act
Key claim: The Federal Kratom Consumer Protection Act would require an FDA hearing and task force on kratom safety while barring the FDA from regulating kratom more restrictively than food, dietary supplements, or dietary ingredients.
Abstract
(S3039 · 118th Congress) Federal Kratom Consumer Protection Act This bill requires the Food and Drug Administration (FDA) to hold a hearing and establish a task force on the health and safety of products with kratom (an herbal substance that produces opioid- and stimulant-like effects). It also prohibits the FDA from regulating kratom products in a manner that is more restrictive as compared to regulations for food, dietary supplements, or dietary ingredients. Latest action (2023-10-04): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Why this matters
The bill would constrain FDA’s authority to treat kratom more strictly than a dietary supplement, effectively blocking scheduling or new-drug pathways while directing the agency to hold a public hearing and convene a task force. For consumers, this preserves current market access to kratom products; for FDA and public health officials, it narrows the tools available to respond to safety concerns.